IP Library Patent Application 17203867
Patent Application
App. No. 17/203,867

COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/203,867
Abstract

The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morphohnoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.

Claims (5)

1 . A composition comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide, or a pharmaceutically acceptable salt or solvate thereof.

2 . A polymorph of 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide, or a pharmaceutically acceptable salt or solvate thereof.

3 . A method of treating or preventing a disease or disorder modulated by a kinase, comprising administering to a subject in need thereof, a pharmaceutically effective amount of the composition of claim 1 .

4 . A method of treating or preventing a disease or disorder modulated by a kinase, comprising administering to a subject in need thereof, a pharmaceutically effective amount of the polymorph of claim 2 .

5 . A method of preparing a polymorph of 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzyl acetamide, or a pharmaceutically acceptable salt or solvate thereof.

Assignments (6)
SECURITY INTEREST Recorded Sep 16, 2022
From: ATHENEX, INC.
To: SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 061119/0681 →
SECURITY INTEREST Recorded Sep 16, 2022
From: ATNX SPV, LLC
To: SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 061119/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2022
From: ATHENEX, INC.
To: ATNX SPV, LLC
Reel/Frame 061071/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2021
From: HANGAUER, DAVID G., JR.; PATRA, DEBASIS; CODY, JEREMY A.; PALMER, GRANT J.; ISBESTER, PAUL K.; SALSBURY, JONATHON
To: KINEX PHARMACEUTICALS, LLC
Reel/Frame 055645/0301 →
CHANGE OF NAME Recorded Mar 19, 2021
From: KINEX PHARMACEUTICALS, LLC
To: KINEX PHARMACEUTICALS, INC.
Reel/Frame 055662/0778 →
CHANGE OF NAME Recorded Mar 19, 2021
From: KINEX PHARMACEUTICALS, INC.
To: ATHENEX, INC.
Reel/Frame 055662/0781 →